Simonova, M <br/><br/>
Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells.  [electronic resource] 

 -  Cancer research  Dec 2000 
 - 6656-62 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antineoplastic Agents--pharmacokinetics<br/>Biotransformation<br/>Cell Division--drug effects<br/>Cell Line<br/>Cysteamine--analogs & derivatives<br/>Fibrosarcoma--drug therapy<br/>Gliosarcoma--drug therapy<br/>Humans<br/>Kidney--cytology<br/>Melanins--biosynthesis<br/>Monophenol Monooxygenase--genetics<br/>Mutation<br/>Phenols--pharmacokinetics<br/>Prodrugs--pharmacokinetics<br/>Propanols--pharmacokinetics<br/>RNA, Messenger--genetics<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Transfection<br/>Tumor Cells, Cultured